Biorepository and Tissue Technology
The Biorepository and Tissue Technology pages have moved. Please visit the website here:
BIOREPOSITORY SHARED RESOURCE
NEW ONLINE SUBMISSION PROCESS (July 2019)
- Instructions on how to submit your tissues
- Do you want to do an immunohistochemistry assay? FAQ
- Submission form
- Histology processing (formalin fixed and frozen tissue)
- Routine H&E and specialized staining
- Antibody optimization and validation
- Immunohistochemistry/Immunofluorescence: single and multiplexing detection assays
- Digital imaging and image storage: AT2 Aperio Scan Scope
- Laser Capture Microdissection (LCM)
- Customized Tissue Micro Array (TMA)
- Pathology consultation
How to RequestThe Biorepository and Tissue Technology Shared Resource (BTTSR) solicits Biospecimen Request Forms for Research (BRFR) and investigators throughout the year with a minimum of paperwork. The application process is simple and straightforward. Contact firstname.lastname@example.org with questions.
- Investigators are requested to submit an inquiry specifying the type and quantity of biospecimen they are interested in obtaining to the BTTSR manger via email email@example.com or firstname.lastname@example.org or submit online inquiry form.
- The BTTSR manager will work with the investigator to verify the availability of the requested biospecimens and further assist the investigator through the distribution process.
- Once the biospecimen type and quantity have been confirmed against the BTTSR inventory, the investigator will be directed to submit a biospecimen request form (BRFR). The BRFR documents information about the proposed research plan as well as the number and type of biospecimens requested.
- Pilot studies in which a minimal amount of biospecimens are needed for test development, quality control, and/or preliminary research, a researcher to request up to 5 biospecimens on a one-time basis for a particular study will be reviewed and approved by Biorepository Director/Management.( This may change upon availability of number of cases for specific type-may require review by Biospecimen Review committee)
- All other studies is used for larger sample size will be reviewed by Biospecimen Request review committee, then will be approved by Biorepository Director/Management.
- The BRFR is submitted to the BTTSR and then reviewed by the biospecimen request review committee (executive committee). Expert opinion may be needed by Organ Site/Disease-Based Advisory Group experts in various fields. A priority review is attached and forwarded to the BTTSR manager and directors to present to the BTTSR executive committee
Factors influencing BRFR priority review are:
a. Scientific merit of the application
b. Experience of the investigator
c. Statistical validity of the study
d. Valid sample size requested to accomplish study
- BTTSR Executive Committee makes the final decision on approving the request for biospecimens and associated data. If the BTTSR is not able to supplement the investigator’s needs, every effort will be made to identify an appropriate resource.
- Upon review by the (OSDBAG) and EC, a BTTSR Manager/ representative is assigned to assist with the distribution of biospecimens and/or to inquire about any scientific issues raised by the (OSDBA).
- Once approved, an official letter/email with a commitment from the BTTSR to provide the necessary biospecimens is sent to the investigator. The approval letter may be incorporated into NIH or other grant applications.
- After the investigator has verified that funding has been secured and IRB approvals have been obtained if needed, biospecimens are released for disbursement. Investigators who fail to obtain funding within six months of receiving their letter of approval will have the approval voided, making those biospecimens available to other investigators.
- If the BRFR is not approved, the investigator will be provided with a letter stating the concerns of the OSDBAG and/or the BTTSR Executive Committee. A BTTSR representative will work with the investigator to resolve any remaining scientific issues in preparation for reconsideration.
- Notification of approval or denial of biospecimens will be emailed approximately 4-6 weeks from BRFR submission and 1-2 weeks from pilot studies.
You may also complete the request form if you require assistance or wish for the BTTSR to contact you. Only members of UC San Diego and C3 (Cancer Center Council) have access to the shared resources.
- Investigators are requested to submit an inquiry specifying the type of biospecimen and disease group they are interested in obtaining prospectively to the BTTSR manger via email email@example.com or firstname.lastname@example.org or submit online inquiry form
- The BTTSR Manager will work with the investigator to evaluate the feasibility of study of the requested prospective collection.
- Investigators are requested to complete biospecimen request forms for research.
- Requests will be reviewed and approved by the biorepository director and management.
- After meeting and with all parties in agreement, SOP and communication workflow will be established prior to the start of the project.
Investigators are requested to submit completed sold tissue request forms along with clinical trial biospecimen collection documents to Tissue Acquisition manager via email email@example.com or firstname.lastname@example.org.
BIOREPOSITORY Please contact Sharmeela Kaushal at email@example.com.
Approved rates July 2019
||Special Stain||$ 10.30
||Frozen Section||$ 4.60
||Multiplexing IHC / IF (per antibody)
||Aperio Digital slide Scanning
||Frozen Tissue, Embedding||$ 3.00
||Pathology Consultation Fee per hour||$185.00
- Patient identity is confidential, all specimens will be coded. The key to the codes will always remain with the Biorepository. No protected health information will be released to researchers.
- The Biorepository does not supply samples to researchers solely for distribution to third parties; those researchers should apply to the Biorepository directly.
- The recipient agrees to acknowledge the contributions of Moores Cancer Center at UC San Diego Health Comprehensive Biorepository in all publications resulting from the use of specimens obtained from the Biorepository. Recommended wording to use in the methods or acknowledgement sections is as follows: "Specimen samples were provided by Moores Cancer Center at UC San Diego Health Comprehensive Biorepository, which is funded by the National Cancer Institute (NCI P30CA23100)."
- Report back to the BTTSR all specimen uses-histology/morphologic analysis, genomics/epigenomics, gene expression, proteomics, etc. (not specific data) and whether there are residual analytes..
M. Valeria Estrada, MD
Moores Cancer Center
3855 Health Sciences Drive
MC0815 Room 5310
La Jolla, CA 92093
Office Phone: (858) 534-8607
- Laarni Gapuz
- Michelle Hong
- Michael Rose
Location: Moores Cancer Center
3855 Health Sciences Drive, Room 5345-Bay 5MM (fifth-floor lab)
Mail Code: MC 0815